問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Division of Radiology

更新時間：2023-09-19

賴盈傑
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

17Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

賴盈傑

List

26Cases

2026-07-01 - 2028-07-31

Phase II

Not yet recruiting
Integrating Precision Imaging for Gastrointestinal Stromal Tumor Patients Treated with Gleevec: A Combined Approach Using Hyperpolarized Carbon-13 MRI, Metabolomics, and Radiomics

  • Condition/Disease

    Gastrointestinal stromal tumor

  • Test Drug

    Hyperpolarized [1-13C]Pyruvate

Participate Sites
1Sites

Not yet recruiting1Sites

2026-09-01 - 2031-12-31

Phase II

Not yet recruiting
A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab Compared to Pembrolizumab Monotherapy in Participants with Advanced Colorectal Adenocarcinoma (CRC) Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR)

  • Condition/Disease

    Colorectal Adenocarcinoma

  • Test Drug

    Pembrolizumab VVD-133214

Participate Sites
2Sites

Not yet recruiting2Sites

2026-01-01 - 2032-03-10

Phase III

Active
A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease who are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes)

  • Condition/Disease

    Metabolic Dysfunction-Associated Steatotic Liver Disease

  • Test Drug

    Retatrutide (LY3437943) Tirzepatide (LY3298176)

Participate Sites
15Sites

Not yet recruiting8Sites

Recruiting7Sites

2026-08-01 - 2031-08-31

Phase II

Not yet recruiting
Cancer immunotherapy research targeting mismatch repair deficiency (dMMR): Multimodal integrated analysis combining hyperpolarized dynamic magnetic resonance (DNP) and artificial intelligence.

  • Condition/Disease

    Newly diagnosed or recurrent gynecological cancers confirmed by histology, including ovarian cancer, cervical cancer, endometrial cancer and other gynecological cancers.

  • Test Drug

    Hyperpolarized [1-13C]Pyruvate

Participate Sites
1Sites

Not yet recruiting1Sites

2023-12-01 - 2027-03-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting3Sites

2026-01-01 - 2030-12-31

Phase I/II

Active
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of NBM-BMX in Combination with Temozolomide in Patients with Newly Diagnosed Glioblastoma Who Completed Study NBM-BMX-003 (the Parent Study)

  • Condition/Disease

    Malignant Neoplasm of Brain

  • Test Drug

    NBM-BMX膠囊

Participate Sites
3Sites

Recruiting3Sites

2024-09-01 - 2032-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-05-01 - 2030-12-31

Phase III

Not yet recruiting
A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas

  • Condition/Disease

    Extrapulmonary Neuroendocrine Cancer (epNEC)

  • Test Drug

    注射用凍晶粉末 注射用懸液劑 注射用懸液劑

Participate Sites
3Sites

Recruiting2Sites

2024-11-01 - 2029-08-31

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2024-11-01 - 2029-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB